Overview:
This one-year, open-label extension of a prior 12-week, double-blind clinical trial assessed the long-term safety and efficacy of once-daily triamcinolone acetonide nasal aerosol in 93 patients with perennial allergic rhinitis (PAR). Patients received one of three daily doses: 110, 220, or 440 micrograms.
The Takeaways:
-
All doses led to sustained symptom improvement over the full year, based on both physician and patient evaluations.
-
Objective improvements were noted in nasal mucosal appearance, nasal secretion quality, nasal eosinophil counts, and decreased need for escape (rescue) medication.
-
Most adverse experiences were mild and unrelated or only remotely related to the study drug.
-
Only six patients withdrew due to adverse events, with just two events (nasal bleeding and headache) possibly related to treatment.
-
No significant changes were observed in vital signs, lab values, or serum cortisol levels, confirming no systemic steroid effect, even with year-long daily use.
Why It Matters:
This study provides important evidence that triamcinolone acetonide can be safely used long term in patients with perennial allergic rhinitis. Despite common concerns about systemic side effects from corticosteroids, the study demonstrated that daily intranasal use over a year maintained clinical efficacy without negatively impacting general health, hormone levels, or nasal tissue.
The Link to Allermi:
Allermi’s nasal sprays may include triamcinolone as part of its evidence-based formulations to support long-term relief from persistent allergy symptoms. This study supports the inclusion of triamcinolone in Allermi’s customized, sustained-use therapies by demonstrating its strong safety profile, consistent efficacy, and excellent tolerability across varying doses—ideal for patients needing daily, year-round management of allergic rhinitis.
For more details, refer to the full study: Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis
